Aptar Pharma and Pulmotree Partner to Develop Liquid Inhaler Platform

Aptar Pharma, a worldwide expert in drug delivery and active material science solutions and services, revealed that they have signed an exclusive partnership with PULMOTREE to oversee the advancement and marketing of their Kolibri Non-Propellant Liquid Inhaler (NPLI) platform. Under the terms of the deal, Aptar Pharma will offer PULMOTREE complete assistance to speed up development, serve as the primary contact for clients, and enhance the Kolibri™ NPLI Platform Technology with Aptar's range of extensive services.

Non-Propellant Liquid Inhalers, including nebulizers and soft-mist inhalers, are being created as a substitute for propellant-driven systems. PULMOTREE's Kolibri makes use of a strong breath-activated Vibrating Mesh technology for aerosol delivery, with special features to improve precise deposition in the lungs. The Kolibri™ technology has won awards and includes advanced connectivity capabilities.

Howard Burnett, Vice President, Global Pulmonary Category, Aptar Pharma, stated, “Pulmotree has solid experience in the NPLI field and Aptar Pharma is delighted to be able to offer the Kolibri™ technology in collaboration with such a knowledgeable partner, to be able to provide full support to all drug developers, from formulation development to patient onboarding.”

Ulf Krüger, CEO of PULMOTREE, stated, “With this alliance, pharmaceutical partners can access an unprecedented portfolio of services from Aptar Pharma as a single source, in the development of combination products to accelerate product development. For PULMOTREE, this important step enables us to continue to grow sustainably and expand our portfolio.”